FGF-1 Mutant Proteins Block Integrin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of FGF-1 signaling through integrins is unclear, particularly how integrins interact with FGF-2 and their role in angiogenesis, tumor growth, and wound healing, as existing methods do not effectively block these processes without affecting heparin binding.
Innovation Solution
Mutations in specific regions of the FGF-1 protein, such as the R50E mutation, are introduced to block integrin binding while maintaining heparin binding, thereby acting as dominant negative mutants to inhibit FGF-1's angiogenic, tumor-promoting, and wound-healing activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If mutations are introduced to block integrin binding of FGF-1, then angiogenic and tumor-promoting activities are inhibited, but heparin binding may be affected
Solution Approach 1:
The patent introduces specific point mutations (R50E, K127E, K128E, K133E, R134E) at discrete locations within the FGF-1 protein structure. These localized mutations selectively disrupt integrin binding interfaces while preserving heparin binding regions, thereby achieving differential modulation of protein interactions based on spatial distribution of binding sites.
Solution Approach 2:
The patent employs amino acid substitution mutations that alter local chemical properties (charge, hydrophobicity) at specific positions. The R50E mutation introduces a negative charge that repels integrins, while heparin binding is maintained through preservation of positively charged residues at heparin interaction sites, demonstrating parameter change at molecular level to achieve selective binding modulation.
2Object-affected harmful factors
If FGF-1 signaling is blocked to inhibit tumor growth, then wound healing may be impaired, but using no treatment allows tumor progression
Solution Approach 1:
The mutant FGF-1 proteins serve as intermediary molecules that selectively interfere with pathological FGF-1-integrin signaling in tumors while allowing physiological FGF-1-heparin signaling to proceed. These engineered proteins act as molecular mediators that distinguish between disease states based on differential integrin expression patterns.
Solution Approach 2:
The patent converts the harmful overactive FGF-1 signaling in tumors into a beneficial therapeutic effect by using mutant FGF-1 proteins that specifically antagonize integrin-mediated tumor growth. The same FGF-1 protein framework that causes tumor growth when overactive is repurposed as a therapeutic agent through targeted mutation to block only the pathological integrin interaction pathway.
3Object-affected harmful factors
If conventional FGF-1 inhibitors are used, then angiogenesis is blocked, but heparin binding is also disrupted affecting normal FGF signaling
Solution Approach 1:
The patent segments the FGF-1 protein into functionally distinct regions by introducing mutations at specific residues (R50, K127-134) that constitute the integrin binding interface. This segmentation allows independent modulation of integrin binding affinity while preserving heparin binding capability, enabling selective inhibition of angiogenesis through integrin blockade without disrupting heparin-mediated FGF signaling pathways.
Data Source
AI summary
The invention relates to an isolated amino acid that can act as an antagonist to FGF signaling, comprising at least a portion of the FGF protein amino acid sequence, and including a mutation in either a) the integrin αvβ3 binding region of FGF-1; or b) the FGFR binding region of FGF-1.